A rare case of refractory acquired thrombotic thrombocytopenic purpura in a twenty-nine-year-old woman carrying dichorionic-diamniotic twins during her third trimester highlights severe diagnostic overlap with obstetric emergencies like preeclampsia. The life-threatening blood disorder, driven by ADAMTS13 deficiency, required emergency delivery and advanced targeted therapy.
Diagnostic Overlap and Clinical Presentation in Twin Gestation
Thrombotic thrombocytopenic purpura represents a rare, life-threatening form of thrombotic microangiopathy characterized by a severe deficiency of the von Willebrand factor-cleaving protease ADAMTS13. While general population incidence sits at roughly two to eleven cases per million annually, pregnancy raises this risk significantly, occurring in approximately one in 25,000 to 100,000 pregnancies. Acquired, immune-mediated forms stem from autoantibodies targeting ADAMTS13 and typically surface during the second or third trimester or the postpartum period.
For the twenty-nine-year-old Ugandan woman carrying twins, the clinical picture arrived with progressive palpitations, shortness of breath on exertion, gum bleeding, right-hand numbness, chest heaviness, and generalized fatigue. Her medical history included a prior cesarean section complicated by fetal distress and a high body mass index. Antenatal visits tracked normal fetal growth alongside persistent mild proteinuria without hypertension, masking the underlying hematologic storm.
Twin pregnancies amplify physiological demands through increased plasma volume, enhanced hypercoagulability, and heightened hemodynamic stress. These factors compound the diagnostic challenge because acquired TTP frequently mimics more common obstetric conditions, including preeclampsia, HELLP syndrome, and atypical hemolytic uremic syndrome. This diagnostic mimicry often delays recognition, driving up maternal and fetal morbidity and mortality.
In Plain English: The Clinical Takeaway
- What TTP Is: Thrombotic thrombocytopenic purpura is a severe blood disorder where microscopic blood clots form in small vessels throughout the body, consuming platelets and shearing red blood cells.
- The Pregnancy Risk: Hormonal and physiological shifts during pregnancy—especially in twin gestations—can trigger autoantibodies that block ADAMTS13, the essential enzyme responsible for breaking down large blood-clotting proteins.
- The Diagnostic Hurdle: Because its symptoms resemble severe preeclampsia or HELLP syndrome, doctors must maintain a high index of suspicion and order specific protease testing to prevent dangerous treatment delays.
Navigating Refractory Disease and Therapeutic Escalation
Standard first-line management for acquired TTP demands urgent therapeutic plasma exchange, commonly known as plasmapheresis, paired with corticosteroids to suppress autoantibody production. However, cases defined as refractory fail to respond adequately to these initial interventions. Such scenarios require escalated immunosuppression and targeted biological agents like caplacizumab, an anti-von Willebrand factor immunoglobulin fragment designed to block the interaction between large von Willebrand factor multimers and platelets.
| Clinical Parameter | Patient Status at Presentation | Standard Management Protocol |
|---|---|---|
| Gestational Age | Third Trimester (Twin Gestation) | Multidisciplinary Obstetric and Hematologic Monitoring |
| Key Laboratory Findings | Profound Thrombocytopenia, MAHA, Schistocytes | Urgent ADAMTS13 Activity Testing |
| First-Line Intervention | Refractory to Initial Care | Therapeutic Plasma Exchange + Corticosteroids |
| Escalated Therapy | Required Due to Non-Response | Targeted Immunosuppression and Caplacizumab |
Research published in medical literature outlines that while plasmapheresis dramatically improves survival rates, refractory presentations demand rapid rescue strategies. Documented experiences utilizing caplacizumab and escalated regimens in pregnancy-associated TTP remain sparse, particularly within twin gestations. Coppo’s scoring system and the PLASMIC score serve as valuable clinical tools to estimate pretest probability and guide immediate action before definitive ADAMTS13 assay results return from the laboratory.
Contraindications and When to Consult a Doctor
Patients exhibiting signs of microangiopathic hemolytic anemia—such as unexplained bruising, petechiae, extreme fatigue, neurological changes, or sudden visual disturbances during pregnancy—require immediate emergency evaluation. Therapeutic plasma exchange carries procedural risks, including allergic reactions to donor plasma, central venous catheter infections, and citrate toxicity leading to hypocalcemia. Expectant mothers presenting with overlapping features of hypertensive disorders of pregnancy must be evaluated by a multidisciplinary team capable of performing rapid hematologic screening.
Clinical Outlook and Multidisciplinary Management
Managing refractory acquired TTP in a complex twin pregnancy underscores the necessity of coordinated care between maternal-fetal medicine specialists and hematologists. Successful emergency delivery, paired with timely diagnostic confirmation via ADAMTS13 testing, is crucial for preserving maternal and neonatal survival. As clinical evidence expands, early recognition and individualized therapeutic rescue will continue to define the standard of care for high-risk obstetric patients facing thrombotic microangiopathies.
References
- National Center for Biotechnology Information. Refractory Thrombotic Thrombocytopenic Purpura to Therapeutic Plasma Exchange Managed with Caplacizumab. PMC9595238.
- Refractory Acquired Thrombotic Thrombocytopenic Purpura in the Third Trimester of a Twin Pregnancy.
- Coppo P, et al. Predictive value of the PLASMIC score and Coppo’s criteria in acquired thrombotic thrombocytopenic purpura. Blood.
